Hanjiang Pharmaceutical

What Hanjiang Pharmaceutical does

Shaanxi Hanjiang Pharmaceutical Group Co., Ltd (Hanjiang) is a privately held, Shaanxi-based pharmaceutical manufacturer founded in 1970 in Hanzhong, operating across four product categories: Active Pharmaceutical Ingredients (APIs) for human use (e.g., Mebendazole, Ambroxol Hydrochloride, Alendronate sodium, Racecadotril, Posaconazole, Rocuronium Bromide, Sugammadex Sodium, Fumarate Bedaquiline), APIs for veterinary use (Fenbendazole, Oxfendazole, Flubendazole, Albendazole, Levamisole HCL, Maropitant Citrate), Steroid APIs and Intermediates (Progesterone, DHEA, Medrogestone, Trenbolone acetate, Vitamin D3, Abiraterone acetate, Estradiol), and Key Intermediates (Imazalil Sulfate/Base). Production is spread across 4 cGMP-compliant API Plants and 2 Intermediates Plants in Hanzhong Hi-tech Industries Development Zone, with capabilities spanning reaction temperatures from -78C to 350C, high-pressure (0-3.5 MPa) and high-vacuum (<10 Pa) operations, chemical resolution and asymmetric synthesis, and specified-polymorph preparation.

The company's business model is B2B contract manufacturing for global pharmaceutical buyers, monetized through custom manufacturing agreements for APIs, intermediates, and finished dosage forms (FDFs). It operates dedicated overseas and domestic sales teams and participates in industry exhibitions such as API China & CHINA-PHARM. Commercial credibility rests on multi-jurisdictional regulatory qualifications (CFDA, FDA, EDQM, PMDA), EU GMP confirmation letters for all APIs, CEP/COS and DMF filings, and ongoing GMP/EHS audits by multinational customers including Johnson & Johnson (Supplier Excellence Process, 2016), Abbott (Strategic Supplier, 2016), Eli Lilly, Bayer, and Merck. Quality, EHS, and high-end process development are anchored by a formal R&D platform (15 National Patents/Technical Know-How, 12 National New Drugs, 4 Exclusive Varieties), an Expert Workstation with Xi'an Jiaotong University's Professor FuQiang and Air Force Medical University academician Zhang Shengyong, and a 2021 school-enterprise alliance with Northwestern University (Xi'an).

Growth is being driven by a sequenced capital program: the 2018 groundbreaking of the High-end APIs project, completion of the High-end Pharmaceutical New Site in 2023, and the 2024 launch of the Innovative Steroid Hormone Drug Formulation industrialization project, which extends the firm from steroid APIs/intermediates into finished dosage forms. Ownership and capital structure are not publicly disclosed; the firm has no disclosed parent company, no external funding rounds, and remains privately held with 501-1,000 employees.

Name

Hanjiang Pharmaceutical

Legal name

Shaanxi Hanjiang Pharmaceutical Group Co., Ltd

Website

https://en.sxhjp.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Shaanxi Hanjiang Pharmaceutical Group is a private Chinese contract manufacturer producing human and veterinary APIs, steroid hormones and intermediates, and finished dosage forms for global pharmaceutical firms including Johnson & Johnson, Abbott, Eli Lilly, Bayer, and Merck.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Active pharmaceutical ingredients
• Contract pharmaceutical manufacturing
• Steroid hormone APIs
• Pharmaceutical intermediates production
• Veterinary pharmaceutical ingredients

Headquarters

HQ city

Hanzhong

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Organization (CMO) Services: Provides CMO services for APIs, Intermediates and FDFs (Finished Dosage Forms) to pharmaceutical companies worldwide. Revenue is generated through manufacturing contracts with pharmaceutical clients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Shaanxi Hanjiang Pharmaceutical Group is a contract manufacturing organization (CMO) that produces active pharmaceutical ingredients (APIs), key intermediates, finished dosage forms (FDFs), and steroid hormones for human and veterinary pharmaceutical companies worldwide. The company operates four cGMP-compliant API plants and two intermediates plants, holding GMP certifications from CFDA, FDA, EDQM, and PMDA, and supplies major pharmaceutical firms including Johnson & Johnson, Abbott, Eli Lilly, Bayer, and Merck.

Product overview

Shaanxi Hanjiang Pharmaceutical Group Co., Ltd is a comprehensive pharmaceutical group engaged in active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms (FDFs). The company's product portfolio consists of four main categories: APIs for Human (human pharmaceutical ingredients), APIs for Veterinary (veterinary pharmaceutical ingredients), Steroids APIs & Intermediates (steroid-based pharmaceuticals), and Key Intermediates. The company operates 4 cGMP-compliant API Plants and 2 Intermediates Plants, offering contract manufacturing services in APIs, Intermediates, and FDFs.

Differentiator

Problem solved

Functional benefit

Products and services

• APIs for Human Active pharmaceutical ingredients manufactured for human pharmaceutical applications, including Mebendazole, Ambroxol Hydrochloride, Alendronate sodium, Racecadotril, Posaconazole, Rocuronium Bromide, Sugammadex Sodium, and Fumarate Bedaquiline. Supplied to enterprise human pharmaceutical companies as contract-manufactured APIs for finished dosage forms.
• APIs for Veterinary Veterinary active pharmaceutical ingredients including Fenbendazole, Oxfendazole, Flubendazole, Mebendazole, Albendazole, Levamisole HCL, and Maropitant Citrate. Supplied to animal health pharmaceutical manufacturers with EU GMP/CEP and EDMF documentation for relevant molecules.
• Steroids APIs & Intermediates Steroid-based active pharmaceutical ingredients and intermediates including Progesterone, DHEA, Dehydroisoandrosterone 3-acetate, Medrogestone, Melengestrol acetate, Trenbolone acetate, Vitamin D3, Abiraterone acetate, Estradiol Hemihydrate, 16,17-a-epoxyprogesterone, and Pregnenolone. Supplied to manufacturers of hormone therapeutics with EU GMP/CEP/COS certifications for select molecules.
• Key Intermediates Key pharmaceutical intermediates for downstream API synthesis, including Imazalil Sulfate, Imazalil Base, and 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl) ethanol. Supplied to pharmaceutical synthesis companies.

Quantifiable outcome

• 15 National Patents/Technical Know-How developed
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Northwestern University (Xi'an)coreStrategic or Co-development Partner · 1 January 2021School-enterprise alliance with Northwestern University to jointly establish a 'school-enterprise joint training base'. Collaboration focused on talent development, R&D, and workforce training in pharmaceutical manufacturing and research.

Scale indicators3 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Dishman Carbogen Amcis: India- and Switzerland-based API and intermediates CDMO offering commercial manufacturing of small molecules, including steroids and niche APIs. Comparable scale and CMO service orientation.
• Porton Pharma Solutions: China-based CDMO providing API and intermediate manufacturing services globally. Directly comparable as a Chinese-headquartered CMO serving multinational pharma with FDA/EDQM-certified capabilities.
• Zhejiang Huahai Pharmaceutical: Major Chinese API manufacturer supplying generic APIs and intermediates to global regulated markets. Comparable product mix (small-molecule APIs, intermediates) and export orientation with similar regulatory certifications.
• WuXi STA (WuXi AppTec subsidiary): Leading global API CDMO and subsidiary of WuXi AppTec. Provides commercial small-molecule API and intermediate manufacturing to multinational pharma, directly competing with Hanjiang for CMO contracts.
• Asymchem Laboratories: Chinese API CDMO offering commercial small-molecule API manufacturing and CMO services to global pharma. Direct competitor to Hanjiang in API contract manufacturing with similar customer base and regulatory footprint.

Broad incumbents

• Aurobindo Pharma: Indian-headquartered global API and finished-dose manufacturer with deep US/EU regulatory presence. A major competitor in the small-molecule API CDMO space, especially for Western pharma customers.
• Divis Laboratories: Indian API and intermediate manufacturer with strong commercial manufacturing capabilities and US/EU regulatory approvals. Competes with Hanjiang for global generic-API CMO contracts at scale.
• Cambrex: US/EU-headquartered small-molecule API CDMO owned by Permira. Provides commercial API manufacturing and process development to pharma, often selected by Western customers seeking non-Indian/non-Chinese supply.
• Jiangsu Hengrui Pharmaceuticals: Large Chinese pharmaceutical company producing APIs, intermediates, and finished dosage forms for global markets. Overlaps with Hanjiang in API manufacturing but operates on a significantly larger scale with a broader portfolio.

Regional players

• Shandong Xinhua Pharmaceutical: Chinese state-owned API and finished-dose manufacturer historically focused on analgesics (aspirin) and other commodity APIs. Comparable domestic positioning in the Chinese API manufacturing landscape.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hanjiang Pharmaceutical